Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model.

Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model.

Afficher d'autres versions (1)

<h4>Background</h4>Medulloblastoma (MB) is the most common brain malignancy in children, and is still responsible for significant mortality and morbidity. The aim of this study was to assess the safety and efficacy of Disulfiram (DSF), an FDA-approved inhibitor of Aldehyde-Dehydrogenase...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Riccardo Serra, Tianna Zhao, Sakibul Huq, Noah Leviton Gorelick, Joshua Casaos, Arba Cecia, Antonella Mangraviti, Charles Eberhart, Renyuan Bai, Alessandro Olivi, Henry Brem, Eric M Jackson, Betty Tyler
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2021
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/e05e4fd3bbde45adb82280054e4266fb
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/e05e4fd3bbde45adb82280054e4266fb

Documents similaires